首页> 外文期刊>World Journal of Gastroenterology >Adrenomedullin in cirrhotic and non-cirrhotic portal hypertension
【24h】

Adrenomedullin in cirrhotic and non-cirrhotic portal hypertension

机译:肾上腺髓质素在肝硬化和非肝硬化门脉高压症中的作用

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: Adrenomedullin (ADM) is a potent vasodilator peptide. ADM and nitric oxide (NO) are produced in vascular endothelial cells. Increased ADM level has been linked to hyperdynamic circulation and arterial vasodilatation in cirrhotic portal hypertension (CPH). The role of ADM in non-cirrhotic portal hypertension (NCPH) is unknown. plasma ADM levels were studied in patients with NCPH, compensated and decompensated cirrhosis in order to determine its contribution to portal hypertension (PH) in these groups. METHODS: There were 4 groups of subjects. Group 1 consisted of 27 patients (F/M: 12/15) with NCPH due to portal and/or splenic vein thrombosis (mean age: 41+-12 years), group 2 consisted of 14 patients (F/M: 6/8) with compensated (Child-Pugh A) cirrhosis (mean age: 46+-4), group 3 consisted of 16 patients (F/M: 6/10) with decompensated (Child-Pugh C) cirrhosis (mean age: 47+-12). Fourteen healthy subjects (F/M: 6/8) (mean age: 44+-8) were used as controls in Group 4. ADM level was measured by ELISA. NO was determined as nitriteitrate level by chemoluminescence. RESULTS: ADM level in Group 1 (236+-61.4 pg/mL) was significantly higher than that in group 2 (108.4+-28.3 pg/mL) and group 4 (84.1+-31.5 pg/mL) (both P<0.0001) but was lower than that in Group3 (324+-93.7 pg/mL) (P=0.002). NO level in group 1 (27+-1.4 μmol/L) was significantly higher than that in group 2 (19.8+-2.8 μmol/L) and group 4 (16.9+-1.6 μmol/L) but was lower than that in Group 3 (39+-3.6 μmol/L) (for all three P<0.0001). A strong correlation was observed between ADM and NO levels (r=0.827, P<0.0001). CONCLUSION: Adrenomedullin and NO levels were high in both non-cirrhotic and cirrhotic portal hypertension and were closely correlated, Adrenomedullin and NO levels increased proportionally with the severity of cirrhosis, and were significantly higher than those in patients with NCPH. Portal hypertension plays an important role in the increase of ADM and NO. Parenchymal damage in cirrhosis may contribute to the increase in these parameters.
机译:目的:肾上腺髓质素(ADM)是一种有效的血管扩张肽。 ADM和一氧化氮(NO)在血管内皮细胞中产生。 ADM水平升高与肝硬化门静脉高压症(CPH)中的动力循环和动脉血管舒张有关。 ADM在非肝硬化门脉高压症(NCPH)中的作用尚不清楚。在患有NCPH,代偿性和代偿性肝硬化的患者中研究血浆ADM水平,以确定这些人群对门脉高压(PH)的贡献。方法:共有4组受试者。第一组由门静脉和/或脾静脉血栓形成(平均年龄:41 + -12岁)引起的NCPH的27例患者(F / M:12/15),第二组包括14例患者(F / M:6 / 8)患有代偿性(Child-Pugh A)肝硬化(平均年龄:46 + -4),第3组由16例(F / M:6/10)失代偿性(Child-Pugh C)肝硬化(平均年龄:47)组成+ -12)。在第4组中以14名健康受试者(F / M:6/8)(平均年龄:44 + -8)作为对照。ADM水平通过ELISA测量。通过化学发光将NO确定为亚硝酸盐/硝酸盐水平。结果:第1组的ADM水平(236 + -61.4 pg / mL)显着高于第2组的(108.4 + -28.3 pg / mL)和第4组的(84.1 + -31.5 pg / mL)(均P <0.0001) ),但低于第3组(324 + -93.7 pg / mL)(P = 0.002)。第1组的NO水平(27 + -1.4μmol/ L)明显高于第2组的(19.8 + -2.8μmol/ L)和第4组的(16.9 + -1.6μmol/ L),但低于第2组3(39 + -3.6μmol/ L)(对于所有三个P <0.0001)。在ADM和NO水平之间观察到强烈的相关性(r = 0.827,P <0.0001)。结论:非肝硬化和肝硬化门静脉高压症患者的肾上腺髓质素和一氧化氮水平均较高,并且密切相关;肾上腺髓质素和一氧化氮水平与肝硬化的严重程度成正比,并且显着高于NCPH患者。门脉高压在ADM和NO的增加中起重要作用。肝硬化的实质损害可能会导致这些参数的增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号